AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
-1.59%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$4.07B
AUM Growth
+$4.07B
(-7.5%)
Cap. Flow
+$67.8M
Cap. Flow
% of AUM
1.67%
Top 10 Holdings %
Top 10 Hldgs %
46.29%
Holding
163
New
17
Increased
15
Reduced
14
Closed
15
Top Buys
| 1 |
Erasca
ERAS
|
$67.3M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$63.7M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$61.9M |
| 4 |
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
|
$42.9M |
| 5 |
Cytokinetics
CYTK
|
$28.6M |
Top Sells
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$72.6M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$68.8M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$38.8M |
| 4 |
Seer Inc
SEER
|
$28.9M |
| 5 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$24.3M |
Sector Composition
| 1 | Healthcare | 90.53% |
| 2 | Consumer Discretionary | 7.15% |
| 3 | Consumer Staples | 0.56% |
| 4 | Materials | 0.44% |
| 5 | Financials | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Lexicon Pharmaceuticals
LXRX
$400M
| $342M | 7.66% | 71,178,364 | – | – |
|
|
WW
2
DELISTED
WW International
WW
| $270M | 6.05% | 14,818,300 | – | – |
|
|
ONC
3
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $236M | 5.28% | 650,000 -200,000 | -24% | -$72.6M |
|
|
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $212M | 4.75% | 1,200,000 +350,000 | +41% | +$61.9M |
|
5
argenx
ARGX
$43.6B
| $174M | 3.9% | 577,308 +77,308 | +15% | +$23.3M |
|
|
XLRN
6
DELISTED
Acceleron Pharma Inc.
XLRN
| $172M | 3.85% | 1,000,000 -400,000 | -29% | -$68.8M |
|
|
7
Seer Inc
SEER
$115M
| $164M | 3.67% | 4,750,000 -838,366 | -15% | -$28.9M |
|
8
Alnylam Pharmaceuticals
ALNY
$58.5B
| $132M | 2.96% | 700,000 -50,000 | -7% | -$9.44M |
|
|
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $89.8M | 2.01% | 1,585,049 -234,137 | -13% | -$13.3M |
|
|
IGMS
10
DELISTED
IGM Biosciences
IGMS
| $88.8M | 1.99% | 1,350,000 +250,000 | +23% | +$16.4M |
|
11
Fate Therapeutics
FATE
$120M
| $85.9M | 1.92% | 1,450,000 +100,000 | +7% | +$5.93M |
|
|
RUBY
12
DELISTED
Rubius Therapeutics, Inc
RUBY
| $74.3M | 1.66% | 4,155,625 -478,166 | -10% | -$8.55M |
|
13
Generation Bio
GBIO
$40.4M
| $70.6M | 1.58% | 2,814,191 | – | – |
|
|
14
Erasca
ERAS
$445M
| $67.3M | 1.51% | +3,172,221 | New | +$67.3M |
|
15
Scholar Rock
SRRK
$3.14B
| $64.4M | 1.44% | 1,950,000 -50,000 | -3% | -$1.65M |
|
16
Amicus Therapeutics
FOLD
$2.34B
| $64M | 1.43% | 6,696,955 +2,946,955 | +79% | +$28.1M |
|
|
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
| $63.7M | 1.42% | +375,000 | New | +$63.7M |
|
|
IMAB
18
I-MAB
IMAB
$340M
| $59.8M | 1.34% | 825,000 +75,000 | +10% | +$5.44M |
|
|
KLRS
19
Kalaris Therapeutics, Inc. Common Stock
KLRS
$76.3M
| $58.2M | 1.3% | 2,323,371 | – | – |
|
|
CERE
20
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $53.1M | 1.19% | 1,800,000 -200,000 | -10% | -$5.9M |
|
|
21
Cytokinetics
CYTK
$4.23B
| $46.5M | 1.04% | 1,300,000 +800,000 | +160% | +$28.6M |
|
|
SAGE
22
DELISTED
Sage Therapeutics
SAGE
| $44.3M | 0.99% | 1,000,000 | – | – |
|
|
OMGA
23
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $42.9M | 0.96% | +2,273,530 | New | +$42.9M |
|
24
Schrodinger
SDGR
$1.44B
| $38.3M | 0.86% | 700,000 -97,445 | -12% | -$5.33M |
|
|
SWTX
25
DELISTED
SpringWorks Therapeutics
SWTX
| $38.1M | 0.85% | 600,000 +100,000 | +20% | +$6.34M |
|